Loading...
XSTO
BIOAb
Market cap1.54bUSD
Apr 15, Last price  
174.00SEK
1D
4.76%
1Q
-14.54%
IPO
491.84%
Name

BioArctic AB

Chart & Performance

D1W1MN
P/E
—
P/S
58.90
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.11%
Rev. gr., 5y
-1.80%
Revenues
257m
-58.22%
41,573,000105,613,000140,706,000713,970,000281,773,00062,347,00023,146,000228,291,000615,995,000257,352,000
Net income
-177m
L
3,710,00057,580,00015,157,000381,602,00088,468,000-68,517,000-119,789,000-11,178,000229,249,000-177,079,000
CFO
-316m
L
-16,434,000675,131,000-135,327,000-200,056,000327,165,000-92,341,000-140,457,000-31,638,000309,694,000-316,332,000
Dividend
May 10, 20191.5 SEK/sh
Earnings
May 15, 2025

Profile

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
URL
https://www.bioarctic.se/
IPO date
Oct 12, 2017
Employees
75
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
257,352
-58.22%
615,995
169.83%
228,291
886.31%
Cost of revenue
486,970
89,627
148,652
Unusual Expense (Income)
NOPBT
(229,618)
526,368
79,639
NOPBT Margin
85.45%
34.88%
Operating Taxes
(12,440)
47,237
11
Tax Rate
8.97%
0.01%
NOPAT
(217,178)
479,131
79,628
Net income
(177,079)
-177.24%
229,249
-2,150.89%
(11,178)
-90.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,982
5,985
BB yield
-0.06%
-0.02%
Debt
Debt current
13,149
2,827
8,857
Long-term debt
95,307
7,131
11,221
Deferred revenue
Other long-term liabilities
Net debt
(404,471)
(1,103,256)
(786,914)
Cash flow
Cash from operating activities
(316,332)
309,694
(31,638)
CAPEX
(7,443)
(12,746)
Cash from investing activities
205,633
(507,485)
(12,763)
Cash from financing activities
5,686
14,064
(2,808)
FCF
(617,896)
483,269
78,111
Balance
Cash
512,927
1,111,567
805,386
Long term investments
1,647
1,606
Excess cash
500,059
1,082,414
795,577
Stockholders' equity
465,596
220,241
Invested Capital
949,170
585,958
576,040
ROIC
82.47%
13.83%
ROCE
49.47%
10.00%
EV
Common stock shares outstanding
88,540
88,487
88,074
Price
199.50
-25.50%
267.80
-1.54%
272.00
128.19%
Market cap
17,663,630
-25.46%
23,696,926
-1.08%
23,956,210
128.23%
EV
17,259,159
22,593,670
23,169,296
EBITDA
(229,618)
544,796
93,823
EV/EBITDA
41.47
246.95
Interest
1,849
379
559
Interest/NOPBT
0.07%
0.70%